GutSee Health

Cover Block

Attribute	Details
Name	GutSee Health
Tagline	AI-driven multi-omics platform and precision phage-based therapies for gut disorders, starting with IBS and IBD.
Headquarters	Warrington, UK
Founded	2024
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

• Website: https://gutseehealth.com/
• LinkedIn: https://uk.linkedin.com/company/gutsee

What an Investor Needs First

GutSee Health is a UK biotech startup using a proprietary AI-driven multi-omics platform to discover and develop precision phage-based therapies for complex gut disorders [GutSee Health, retrieved 2024]. Founded in late 2024, the company is building its discovery engine and initial therapeutic candidates while embedded within a network of academic and venture-builder support.

The founding story centers on Dr. Joanna Wiecek, a UCL researcher and microbiome expert, who launched the company to translate her scientific work into a platform for causal microbiome re-engineering [UCL, Nov 2024]. The core product is a dual-component offering: a bespoke AI discovery platform that fuses multi-omics data to decode disease signatures, and a pipeline of precision therapies using proprietary phage-biotic and nuclease-based tools designed to modulate the gut ecosystem [Perplexity Sonar Pro Brief, retrieved 2024]. This platform-plus-therapeutic approach aims to move beyond symptom management for conditions like Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

Dr. Wiecek is joined by co-founder Dr. Ketaki Mhatre, whose background includes biotech innovation and project management [LinkedIn, retrieved 2024]. The company has secured initial pre-seed venture capital from Zinc VC and is a participant in their structured venture-builder program [Zinc, retrieved 2024]. The business model is B2B, with future revenue likely stemming from therapeutic licensing or platform partnerships.

Over the next 12-18 months, the key milestones to watch are the validation of the AI platform's predictive capabilities, the selection of a lead therapeutic candidate for preclinical development, and the securing of a strategic research collaboration or grant. The company's affiliation with UCL and location at the STFC Daresbury science park provide critical non-dilutive infrastructure support.

Data Accuracy: YELLOW -- Core company claims and team background are confirmed by company and university sources; funding details and commercial progress are not fully disclosed.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Inside the Company

GutSee Health is a UK biotech startup founded in September 2024, emerging from the University College London (UCL) ecosystem. The company was incorporated as GUTSEE HEALTH LIMITED on September 11, 2024, with its registered office at the Campus Technology Hub within the STFC Daresbury Laboratory in Warrington [GOV.UK, retrieved 2026].

The founding narrative centers on Dr. Joanna Wiecek, a UCL alumna and microbiome researcher, who co-founded the company to translate academic insights into targeted therapies for chronic gut conditions [UCL, Nov 2024]. A key early milestone occurred in late 2024 when GutSee joined the Zinc VC Programme and secured an initial pre-seed investment from Zinc VC [GutSee Health, retrieved 2024] [Zinc, retrieved 2024].

Subsequent public activity includes participation in ecosystem events like the London Demo Day in 2025 [LinkedIn, retrieved 2024]. The company remains in the R&D and platform development phase.

Data Accuracy: GREEN -- Confirmed by company registry (GOV.UK), university press (UCL), and investor portfolio (Zinc).

Under the Hood

The company's core proposition is a dual-component approach: a proprietary discovery platform feeding a pipeline of novel therapeutics. GutSee Health is developing a "bespoke multi-omics AI-Discovery Platform" designed to decode complex interactions between the gut microbiome and its human host [Perplexity Sonar Pro Brief, retrieved 2024]. This platform fuses genomic, metagenomic, and other biological data layers with machine learning models to identify disease-specific microbial signatures [UCL, Nov 2024].

These therapies represent the intended commercial product. The company aims to move beyond symptom management to "re-engineer the disrupted gut microbiome & ecosystem, addressing the root causes of gut diseases" [GutSee Health, retrieved 2024]. Its therapeutic toolkit includes "proprietary nuclease-based / CRISPR-like tools and phage-biotic therapeutics" for targeted microbiome modulation [Perplexity Sonar Pro Brief, retrieved 2024]. The initial clinical focus is on Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) [Perplexity Sonar Pro Brief, retrieved 2024].

Data Accuracy: YELLOW -- Core product claims are consistent across the company website and secondary summaries, but detailed technical specifications and platform validation data are not public.

Market Research

The market for advanced diagnostics and therapeutics targeting the gut microbiome is expanding rapidly. The global irritable bowel syndrome treatment market was valued at $2.8 billion in 2023 and is projected to grow to $4.7 billion by 2033 [Precedence Research, 2024]. The broader microbiome therapeutics market is forecast to reach $1.7 billion by 2030 [Grand View Research, 2024].

Metric	Value
IBS Treatment Market 2023	$2.8B
IBS Treatment Market 2033	$4.7B
Microbiome Therapeutics Market 2030	$1.7B

Data Accuracy: YELLOW -- Market sizing drawn from third-party analyst reports; specific TAM for AI-driven phage therapy platforms not yet publicly modeled.

Competition and Substitutes

GutSee Health enters a specialized segment of the microbiome therapeutics and diagnostics market.

Company	Positioning	Stage / Funding	Notable Differentiator
GutSee Health	AI-driven multi-omics platform for discovery of precision phage-based therapies for IBS/IBD.	Pre-Seed, Zinc VC (amount undisclosed).	Combines multi-omics AI discovery with proprietary phage-biotic and nuclease-based therapeutic tools.
Eligo Bioscience	Precision microbiome editing using CRISPR-based technologies to target specific bacterial strains.	Series B ($30M, 2023).	Focus on engineered phage-derived particles for precise gene editing of the microbiome.
Microbiotica	Discovery and development of live bacterial therapeutics and biomarkers for IBD and immuno-oncology.	Venture-backed, partnered with Genentech and Cambridge Innovation Capital.	Clinically validated microbiome-derived biomarkers and a proprietary culture collection.
Genetic Analysis (GA)	Standardized microbiome testing and analysis for clinical and research use.	Publicly traded on Euronext Growth Oslo.	Focus on diagnostic hardware and standardized test kits (GA-map®).

Data Accuracy: YELLOW -- Competitor details drawn from secondary industry reports; subject company positioning confirmed by primary sources.

Opportunity

If GutSee Health successfully translates its platform from discovery into a pipeline of validated therapeutics, it could capture a significant portion of the high-value precision microbiome market. The headline opportunity is the creation of a category-defining, AI-driven biotech platform that generates both diagnostic insights and a pipeline of targeted therapies for complex gut disorders.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated platform thesis and comparable market events, but GutSee's own path to these outcomes remains unproven and early-stage.

Sources

1. [GutSee Health, retrieved 2024] Home - GutSee Health | https://gutseehealth.com/
2. [UCL, Nov 2024] UCL startup GutSee joins Zinc VC Programme | https://www.ucl.ac.uk/enterprise/news/2024/nov/ucl-startup-gutsee-joins-zinc-vc-programme
3. [Zinc, retrieved 2024] Gutsee Health | Zinc | https://www.zinc.vc/portfolio/gutsee-health/
4. [LinkedIn, retrieved 2024] GutSee Health | https://uk.linkedin.com/company/gutsee
5. [Perplexity Sonar Pro Brief, retrieved 2024] AI-driven multi-omics platform and precision phage-based therapies for gut disorders | [Source summary from structured research]
6. [GOV.UK, retrieved 2026] GUTSEE HEALTH LIMITED people - Find and update company information | https://find-and-update.company-information.service.gov.uk/company/15954302/officers
7. [Technology Networks, retrieved 2024] UK Biotech Start-Ups Embark on Discovery Spark Program | https://www.technologynetworks.com/biopharma/blog/a-glimpse-into-the-technologies-behind-upcoming-uk-biotech-start-ups-393316
8. [BioArk, Dec 2025] Antibiotic resistance: interview with Joanna Wiecek | https://www.bioark.ch/de/news/antibiotic-resistance-interview-with-joanna-wiecek-10201
9. [Labiotech.eu, retrieved 2026] 11 microbiome biotech companies to watch in 2025 | https://www.labiotech.eu/best-biotech/microbiome-biotech-companies/
10. [Inside Precision Medicine, retrieved 2026] The Top Five Emerging Microbiome Startups Following Their Gut | https://www.insideprecisionmedicine.com/topics/precision-medicine/the-top-five-emerging-microbiome-startups-following-their-gut/
11. [Microbiome Therapeutics Innovation Group, retrieved 2026] Member Companies - Microbiome Therapeutics Innovation Group | https://microbiometig.org/member-companies/
12. [Precedence Research, 2024] Irritable Bowel Syndrome Treatment Market Size, Share, Growth Report 2033 | [Market sizing report referenced in analysis]
13. [Grand View Research, 2024] Microbiome Therapeutics Market Size, Share & Trends Analysis Report 2030 | [Market sizing report referenced in analysis]
14. [Gastroenterology, 2023] Unmet Therapeutic Needs in Irritable Bowel Syndrome | [Academic journal referenced in analysis]
15. [Nature Reviews Gastroenterology & Hepatology, 2024] Phage therapy and microbiome modulation | [Academic journal referenced in analysis]